Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA VaccinationArticle Published on 2022-10-172022-11-15 Journal: The Journal of Infectious Diseases [Category] [DOI] 10.1093/infdis/jiac178 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기
Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 VaccineArticle Published on 2022-10-152022-11-15 Journal: International Journal of Molecular Sciences [Category] [DOI] 10.3390/ijms232012333 PMC 바로가기
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesArticle Published on 2022-10-132022-11-15 Journal: Frontiers in Immunology [Category] [DOI] 10.3389/fimmu.2022.1016927 PMC 바로가기
Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritisArticle Published on 2022-10-122022-11-15 Journal: Frontiers in Immunology [Category] [DOI] 10.3389/fimmu.2022.960001 PMC 바로가기
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design studyArticle Published on 2022-10-112022-11-16 Journal: The BMJ [Category] [DOI] 10.1136/bmj-2022-072065 PMC 바로가기
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE networkArticle Published on 2022-10-082022-11-15 Journal: Trials [Category] [DOI] 10.1186/s13063-022-06791-y PMC 바로가기
Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in SpainArticle Published on 2022-10-072022-11-15 Journal: Scientific Reports [Category] [DOI] 10.1038/s41598-022-19537-2 PMC 바로가기
Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patientsArticle Published on 2022-10-062022-11-15 Journal: Frontiers in Immunology [Category] [DOI] 10.3389/fimmu.2022.1004045 PMC 바로가기
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulationsArticle Published on 2022-10-062022-11-15 Journal: Vaccine [Category] [DOI] 10.1016/j.vaccine.2022.08.024 PMC 바로가기